English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Numerous studies have demonstrated the superiority of rosuvastatin over other statins in the treatment of cardiovascular disease. It has been proven that rosuvastatin is more effectively lowers low-density lipoprotein cholesterol in patients with cardiovascular disease than other members of this drug group. Despite the known mechanisms of action of statins on blood lipids, their effective use in patients with cardiovascular disease, as well as side effects, the influence of these drugs on the fatty acid spectrum of lymphocyte (LC) membrane phospholipids in patients with ischemic heart disease remains unexplored. The results of the studies cited in the article indicate that, in patients with unstable angina who received the therapy that included rosuvastatin, unlike patients receiving the basic treatment with atorvastatin, the relative phosphate lipid contents of palmitic, stearic, and stearin arachidonic polyunsaturated fatty acids and the amount of unsaturated fatty acids are normalized, which testifies to the stabilization of membranes as dynamic structures.

Effect of atorvastatin and rosuvasta tin on the fatty acid spectrum of lymphocyte membranes in patients with unstable angina